血清肿瘤标志物在胰腺肿瘤中的临床应用和研究

Clinical Application and Research of Blood Serum Tumor Markers in Pancreatic Cancer

目的探讨血清肿瘤标志物CEA、CA19-9、CA50水平与胰腺癌分期和肿瘤大小的关系。方法分别测定35例胰腺癌和36例慢性胰腺炎患者血清CEA、CA19-9与CA50水平。外科手术和病理学判定TNM分期和肿瘤大小,分析两者之间的关系。结果血清CEA、CA19-9、CA50对胰腺癌诊断的敏感性分别为42%、82%、74%。特异性分别为75%、83%、77%。Ⅲ+Ⅳ期的CA19-9和CA50水平明显高于Ⅰ+Ⅱ期患者(P<0.05),CEA超过正常值者仅见于Ⅲ期以上胰腺癌患者。TS3+TS4组的CEA、CA19-9、CA50水平比TS1+TS2组明显增高(P<0.05)。结论胰腺癌血清肿瘤标志物水平与胰腺癌分期和肿瘤大小有一定关系。

Objective To study on the relationship between serum levels of CEA,CA19-9, CA50 with the TNM staging and the tumor sizes in patients with pancreatic cancer. Methods The serum concentrations of CEA, CA19-9 and CA50 were determined in 35 patients with pancreatic cancer and 36 patients with chronic pancreatitis. Pancreatic cancer TNM staging and tumor size were studied by operation or pathology. The relationship between the tumor marker levels with the TNM staging and tumor size were analyzed. Results The sensitivities of CEA, CA19-9 and CA50 in diagnosing the pancreatic cancer were 42% ,82% and 74% ,respectively;and their specificities were 75% ,83% and 77% ,respectively. The levels of CA19-9 and CA50 in patients at stage Ⅲ＋ Ⅳ were higher than those at stage Ⅰ ＋ Ⅱ （P 〈0.05）. There was no abnormal CEA found in patients at stage Ⅰ ＋ Ⅱ. The levels of CEA,CA19-9 and CA50 in TS3 ＋ TS4 groups were higher than those in TS1 ＋ TS2 groups （P 〈 0.05）. Conclusion Serum tumor markers levels are associated with the TNM staging and the tumor sizes in pancreatic cancer patients.